T1	Participants 47 100	hemodialysis patients during growth hormone treatment
T2	Participants 114 161	Adult patients with chronic renal failure (CRF)
T3	Participants 646 686	20 adult enfeebled hemodialysis patients
T4	Participants 688 805	9 patients were treated with a single daily subcutaneous injection of recombinant human growth hormone (rhGH) 4 IU/m2
T5	Participants 810 836	11 with placebo injections
